Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy

Open Access 30-09-2024 | Liraglutide

Effect of preoperative liraglutide 3.0 mg on incidence of intraoperative adhesions in laparoscopic sleeve gastrectomy

Authors: G. Martines, C. Giove, B. Carlucci, A. Dezi, C. Ranieri, M. T. Rotelli, M. De Fazio, G. Tomasicchio

Published in: Surgical Endoscopy

Login to get access

Abstract

Introduction

Liraglutide has shown promising results in the field of bariatric surgery, preparing patients for surgery. However, chronic therapy is often correlated with gastrointestinal disorders, such as subclinical pancreatitis. The aim of this study was to evaluate the incidence of intraoperative adhesions and post-operative complications in patients undergoing laparoscopic sleeve gastrectomy (LSG) with or without prior therapy with liraglutide.

Methods

Clinical records of patients affected by obesity who underwent LSG between March 2017 and October 2022 were retrospectively reviewed using a prospectively maintained database. Patients were separated into two groups: those managed with preoperative liraglutide for 24 weeks prior to LSG, and those without prior medical therapy. Demographic data, operative time, intraoperative adhesions, and postoperative complications were reported and compared between two groups.

Results

Ninety-three patients underwent LSG without prior medical therapy, while 87 were treated with liraglutide before surgery. There were no significant differences in terms of gender, age, and comorbidities. After treatment with liraglutide, weight (117 vs 109 kg) and BMI (45 vs 42.2 kg/m2) were statistically lower than the group with no prior treatment to surgery. Thirty-two (37%) patients of the group treated with liraglutide had intraoperative adhesion vs nine (10%) patients of the control group (p < 0.005). There were no differences recorded between the two groups concerning post-operative complications.

Conclusion

Liraglutide has introduced a new way to treat obesity, improving weight loss and comorbidities. Gastrointestinal disorders, such as subclinical pancreatitis, associated with GLP-1 analogue could explain the elevated incidence of intraoperative adhesions during bariatric surgery.
Literature
1.
Misra A, Khurana L (2011) Obesity-related non-communicable diseases: South Asians vs White Caucasians. Int J Obes (Lond) 35:167–187CrossRefPubMed
2.
Syn NL, Cummings DE, Wang LZ, Lin DJ, Zhao JJ, Loh M, Koh ZJ, Chew CA, Loo YE, Tai BC, Kim G, So JB, Kaplan LM, Dixon JB, Shabbir A (2021) Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet 397:1830–1841CrossRefPubMed
3.
Daniel Guerron A, Portenier DD (2016) Patient selection and surgical management of high-risk patients with morbid obesity. Surg Clin North Am 96:743–762CrossRefPubMed
4.
5.
Bays H, Pi-Sunyer X, Hemmingsson JU, Claudius B, Jensen CB, Van Gaal L (2017) Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Curr Med Res Opin 33:225–229CrossRefPubMed
6.
7.
Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD (2022) Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab Syndr 16:102427CrossRefPubMed
8.
Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH (2017) Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care 40:839–848CrossRefPubMed
9.
Sauerland S, Angrisani L, Belachew M, Chevallier JM, Favretti F, Finer N, Fingerhut A, Garcia Caballero M, Guisado Macias JA, Mittermair R, Morino M, Msika S, Rubino F, Tacchino R, Weiner R, Neugebauer EA, European Association for Endoscopic S (2005) Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc 19:200–221CrossRefPubMed
10.
Kim YI (2013) Comparative study for preventive effects of intra-abdominal adhesion using cyclo-oxygenase-2 enzyme (COX-2) inhibitor, low molecular weight heparin (LMWH), and synthetic barrier. Yonsei Med J 54:1491–1497CrossRefPubMedPubMedCentral
11.
Diamond MP, Wexner SD, diZereg GS, Korell M, Zmora O, Van Goor H, Kamar M (2010) Adhesion prevention and reduction: current status and future recommendations of a multinational interdisciplinary consensus conference. Surg Innov 17:183–188CrossRefPubMed
12.
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196CrossRefPubMed
13.
Lando HM, Alattar M, Dua AP (2012) Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 18:472–477CrossRefPubMed
14.
Liu L, Chen J, Wang L, Chen C, Chen L (2022) Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne) 13:1043789CrossRefPubMed
15.
Butler PC, Elashoff M, Elashoff R, Gale EA (2013) A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 36:2118–2125CrossRefPubMedPubMedCentral
16.
Hakim M, Fathi M, Abdulraziq M, Al Shehri M (2022) Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy. Surg Endosc 36:8503–8508CrossRefPubMed
17.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP, Obesity S, Prediabetes NNSG (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:11–22CrossRefPubMed
18.
Reames BN, Bacal D, Krell RW, Birkmeyer JD, Birkmeyer NJ, Finks JF (2015) Influence of median surgeon operative duration on adverse outcomes in bariatric surgery. Surg Obes Relat Dis 11:207–213CrossRefPubMed
19.
Schwartz ML, Drew RL, Chazin-Caldie M (2003) Laparoscopic Roux-en-Y gastric bypass: preoperative determinants of prolonged operative times, conversion to open gastric bypasses, and postoperative complications. Obes Surg 13:734–738CrossRefPubMed
20.
Russell E, Herberg JDP, Grover BT (2024) Use of pre-operative glucagon-like peptide 1 agonists and impact on weight loss following bariatric surgery. SOARD 2024:S15–S15
Metadata
Title
Effect of preoperative liraglutide 3.0 mg on incidence of intraoperative adhesions in laparoscopic sleeve gastrectomy
Authors
G. Martines
C. Giove
B. Carlucci
A. Dezi
C. Ranieri
M. T. Rotelli
M. De Fazio
G. Tomasicchio
Publication date
30-09-2024
Publisher
Springer US
Published in
Surgical Endoscopy
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-024-11231-w
SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

  • Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now
Image Credits